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Abstract
Introduction: The aim of this study was to compare various coplanar and
non-coplanar 3-dimensional conformal radiation therapy (3DCRT) beam
arrangements for the delivery of stereotactic ablative radiation therapy (SABR)
to patients with early stage lung cancer, based on the dosimetric criteria from
the Radiation Therapy Oncology Group (RTOG) 1021 protocol. Methods: Ten
medically inoperable lung cancer patients eligible for SABR were re-planned
using three different coplanar and three different non-coplanar beam
arrangements. The plans were compared by assessing planning target volume
(PTV) coverage, doses to normal tissues, the high-dose conformity
(conformity index) and intermediate dose spillage as defined by the D2cm, (the
dose at any point 2 cm away from the PTV), and the R50% (the ratio of the
volume of half the prescription dose to the volume of the PTV). Results:
Sixty plans in total were assessed. Mean PTV coverage with the prescription
isodose was similar between coplanar (95.14%) and non-coplanar (95.26%)
techniques (P = 0.47). There was significant difference between all coplanar
and all non-coplanar fields for the R50% (P < 0.0001) but none for the D2cm
(P = 0.19). The seven and nine field beam arrangements with two non-
coplanar fields had less unacceptable protocol deviations (10 and 7) than the
seven and nine field plans with only coplanar fields (13 and 8). The 13 field
coplanar fields did not improve protocol compliance with eight unacceptable
deviations. The 10 field non-coplanar beam arrangement achieved best
compliance with the RTOG 1021 dose criteria with only one unacceptable
deviation (maximum rib dose). Conclusion: A 3DCRT planning technique
using 10 fields with ≥6 non-coplanar beams best satisfied high and
intermediate dose constraints stipulated in the RTOG 1021 trial. Further
investigations are required to determine if minor protocol deviations should
be balanced against efficiency with the extended treatment times required to
deliver non-coplanar fields and if treatment times can be improved using
novel intensity modulated techniques.
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Introduction
Lung cancer is the fifth most common cancer in Australia
but the most common cause of cancer-related deaths.1
The majority of patients diagnosed with early stage (I/IIa)
non-small cell lung cancer are able to undergo surgical
resection. However, 33% of patients present with co-
morbidities that make them unfit for surgery.2 For
these patients, local failure following conventionally
fractionated external beam radiation therapy is in the
order of 40% and treatment involves 20–30 attendances
over 4–6 weeks.3 Stereotactic ablative radiation therapy
(SABR) has emerged as an alternative treatment option
capable of delivering a higher biologically effective dose
(BED) resulting in higher local control rates in excess of
85%.2,4–6 SABR involves the delivery of hypofractionated
schedules of >7.5 Gy per day in 1–5 fractions, typically to
a BED10 of >100 Gy.
7 SABR utilises advanced
immobilisation, motion management and image guidance
systems and utilises complex planning techniques to
achieve highly conformal, ablative doses with rapid dose
fall off outside the planning target volume (PTV).8–10
Dosimetric parameters such as high- and intermediate
dose constraints have been established in an attempt to
quantitatively describe the quality of SABR plans in
regards to dose fall off and conformity. The high-dose
constraint refers to the conformity of the prescription
isodose to the PTV, measured using the conformity index
(CI). The intermediate dose constraints refer to both the
maximum dose to any point 2 cm from the edge of the
PTV (D2cm) and the ratio of the volume encompassed by
the 50% isodose line (relative to the prescription dose,
PD) to the volume of the PTV (R50%). These planning
quality metrics have been integrated into Radiation
Therapy Oncology Group (RTOG) trial protocols
evaluating lung SABR.11–13 The high- and intermediate
dose constraints are important dose metrics as a rapid
dose fall-off minimises toxicity.14
Several groups have reported on their experiences with
SABR beam arrangements that were required to meet the
high- and intermediate dose constraints.15–17 Both Lim
et al.15 and Fakiris et al.17 report on using multiple non-
coplanar beams to achieve SABR constraints. However,
Richmond et al.16 report that in 17 of 19 cases, seven
equidistant coplanar fields produced no more than two
minor deviations. This group, however, used high- and
intermediate dose constraints from the ROSEL study,18
which are more relaxed than those of RTOG.
Furthermore, both Lim et al.15 and Fakiris et al.17 did not
apply tissue heterogeneity corrections, which when
reported by Xiao et al.19 is shown to change the value of
an acceptable and unacceptable protocol deviation. This
study was therefore designed to compare different beam
arrangements (coplanar and non-coplanar) for lung SABR
taking into account heterogeneity correction to determine
which best satisfies RTOG 1021 dosimetric criteria.
Methods and Materials
Patient selection
Institutional ethical approval was granted for ten patients
that had previously received treatment for lung cancer at
the Princess Alexandra Hospital and who met the SABR
eligibility criteria to be randomly identified from our
local radiation oncology information system database.
Patient eligibility was defined as early stage (IA/B or IIA),
with the PTV <5 cm in the largest dimension and the
gross tumour volume (GTV) >2 cm away from the
proximal bronchial tree.
Simulation
All patients had been positioned in the supine position
with their forearms above head in a Civco (Coralville,
Iowa) Vac-lok cushion. All patients had a 4-dimensional
computed tomography (4DCT) scan with 10 respiratory
phase bins created. A free breathing scan with a 2 mm
slice thickness was obtained with the length including the
entire lung volume and exported and registered to the
4DCT in Pinnacle v9.4 (Philips Medical Systems,
Stockholm, Sweden). The free breathing scan was
nominated as the primary data set for planning purposes.
The GTV was contoured on each of the respiratory
phases and then combined to create an internal target
volume (ITV). The PTV was created by expanding the
ITV 5 mm isotropically. In addition, the organs at risk
(OAR) were contoured and their constraints are listed in
Table 1. The chest wall (CW) was defined as a 2 cm
expansion anteriorly, posteriorly and laterally on the
ipsilateral lung, excluding the mediastinum, vertebral
body and sternum. A 2 cm expansion of the PTV was
used to create the D2cm. All reported doses are to a
minimum clinically relevant measurable volume of
0.03 cm3.
Dose prescribing
Patients were planned to receive a PD of 54 Gy in three
fractions at the periphery of the PTV. Dose was
prescribed so the covering (prescription) isodose fell
between 59% and 90% of the absolute maximum dose in
the plan as recommended by RTOG.11–13,20 PTV coverage
was required to be >95% for the PD (PTV54Gy), and
>99% for 90% of the PD (PTV48.6Gy). All D2cm and R50%
constraints (RTOG 1021) are relative to PTV size
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(Table 2) and were interpolated as required for each
patient. In this study, the CI was calculated using the
following equation:
CI ¼ ðTVPTVÞ
2
TV PIV ;
where TVPTV is defined as the total volume of PTV
covered by the covering isodose (54 Gy), TV is defined as
the total volume of the PTV and PIV is defined as the
total volume of the covering isodose in the patient.21 A
CI value of ≥0.75 was desirable, with ≥0.65 constituting
an acceptable deviation and anything <0.65 was
considered unacceptable.
Treatment planning
All plans were constructed by a single planner and
calculated with Pinnacle v9.4 using the collapsed cone
convolution (CCC) algorithm with a grid spacing of
0.25 cm3. The CCC algorithm is a type B algorithm and
accounts for changes in lateral electron transport and
should therefore be used for lung tumour treatments. As
large differences are noted in calculations, the dose
prescription and spillage guidelines (Table 2) that were
calculated using a type A or water based algorithm (0236)
should not be used when using a type B algorithm.8,19 As
a consensus does not exist in the literature, beam
arrangements were derived from multiple sources to
account for a wide range of recommendations. RTOG
recommends the use of seven beams as a minimum,
where as a retrospective review of local departmental
preference showed nine beams, including two non-
coplanar beams was typical. Furthermore, the use of 10
beams, with six being non-coplanar is recommended by
Ding et al. while the European Organisation for the
Research and Treatment of Cancer (EORTC) recommend
against non-coplanar beams due to the associated increase
in treatment times.8,20 Lastly, a 13 field evenly spaced all
coplanar arrangement was also investigated to assess if
number of coplanar beams, or non-coplanar beams
improves plan quality. Treatment plans investigated in
this study therefore included the following: 7 coplanar
beams (7C), 9 coplanar beams (9C), 13 coplanar beams
(13C), 7 beams including 2 non-coplanar beams (7NC), 9
beams including 2 non-coplanar beams (9NC) and 10
beams with 6 or more non-coplanar beams (10NC).
Starting beam angles for a right-sided tumour where G
represents gantry and angle and F represents floor angle
were: 7C technique, G180, G210, G240, G270, G300,
G330 and G10, all with a floor of 0 (F0), the 9C
technique, G180, G210, G240, G270, G300, G330 and
G10, G40, G100 all with a floor of 0 (F0), the 7NC
technique, G210F0, G330F90, G240F0, G270F0, G300,
G330 and G30F90, the 9NC technique G210F0, G330F90,
G240F0, G270F0, G300, G330 and G30F90, G40F0 and
G100F0. The 10NC used beam angles as referenced by
Ding et al.20 and the 13C technique used 13 evenly
spaced beams around 360° with a floor of 0. Beam angles
were adjusted as necessary to achieve protocol
compliance. Angles were mirrored for a left-sided
tumour. All beam angles were checked for clearance on
the treatment machine.
Every attempt was made to ensure the 7C field
techniques used beam angles entering only through the
ipsilateral lung to avoid unnecessary exposure of the
contra-lateral lung to radiation. However, the 9C field
technique required beams entering through the contra-
lateral to avoid overlapping beams and consequently
increasing the low- and intermediate dose wash. Two
coplanar beams in the 7C and 9C techniques were made
non-coplanar for the 7NC and 9NC techniques. These
were typically superior anterior and superior posterior
oblique fields. The 10NC technique used 6 non-coplanar
beams and only introduced more non-coplanar beams if
the D2cm or R50% values were unachievable. Beam weights
were manipulated by the planner to achieve isotropic
Table 1. Organ at risk dose constraints.
Organ Constraint(s)
Spinal cord 18 Gy < 0.35 cm3
12.3 Gy < 1.2 cm3
MPD < 21.9 Gy
Brachial plexus 20.4 Gy < 3 cm3
MPD < 24 Gy
IVC 39 Gy < 10 cm3
MPD < 49 Gy
SVC 39 Gy < 10 cm3
MPD < 49 Gy
Aorta 39 Gy < 10 cm3
MPD < 49 Gy
Pericardium 24 Gy < 15 cm3
MPD < 30 Gy
Trachea 15 Gy < 4 cm3
MPD < 30 Gy
Combined lungs – ITV 11.4 Gy < 1000 cm3
10.5 Gy < 1500 cm3
Oesophagus 17.7 Gy < 5 cm3
MPD < 25.2 Gy
Rib 40 Gy < 5 cm3
MPD < 50 Gy
CW 30 Gy < 30 cm3 (<70 cm3 for
tumours on the CW)
Skin 30 Gy < 10 cm3
MPD < 33 Gy
IVC, inferior vena cava; SVC, superior vena cava; ITV, internal target
volume; CW, chest wall; MPD, maximum point dose (defined as
≥0.03 cm3).
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dose fall off in accordance with criteria listed in Table 2,
aside from the 13C technique, where each beam was
given equal weighting and only adjusted if OAR were
over tolerance. PTV coverage below 95% was only
allowed if the spinal cord or brachial plexus constraints
could not be met.
A structure for creating a block margin was created by
shrinking the PTV 2 mm laterally, anteriorly and
posteriorly and expanding 2 mm superiorly and
inferiorly. The multi-leaf collimator (MLC) shielding of
each beam was then shaped to the structure. This
structure was adjusted as necessary to achieve PTV
coverage and a prescription isodose between 59% and
90%. The block margin structure results in the MLC
shielding the periphery of the PTV such that the
prescription isodose falls into the beam penumbra,
allowing for a steep dose gradient beyond the PTV. An
expansion superior and inferior to the block margin
structure was needed to account for limitations of non-
coplanar beams. Even though non-coplanar beams are
used, most of the dose is still delivered across the
transverse plane. Dose in all plans was normalised to the
maximum dose in the plan which was generally located
in the centre of the PTV.
Planning priorities and protocol deviations
Planning priorities were first and foremost, to adhere to
the spinal cord and brachial plexus constraint, secondly
to meet the high- and intermediate dose constraints
and lastly to meet the remaining OAR constraints.22
The RTOG 1021 protocol defines plan deviations as
either being none or acceptable, with an unacceptable
deviation for plans that exceeds the acceptable
deviation. With all plans, every attempt was made to
achieve the no deviation values (Table 2). However,
some situations resulted in unavoidable digression from
the priorities. For instance, if an OAR is immediately
adjacent to the PTV, then adhering to the maximum
dose constraint could be challenging. In this instance
the maximum dose to the adjacent OAR can be 105%
of the PD and registering as an acceptable deviation.
However, all volumetric dose constraints to the
structure must still be respected. Furthermore, to avoid
clinical toxicity due to overdosing OAR, the dose fall
off may be weighted so it is not isotropic, but still falls
within the acceptable deviation. Plans were considered
clinically suitable if there were no unacceptable
deviations from protocol.
To represent protocol deviations with respect to the
D2cm and R50% constraints, a scoring system was devised.
As intermediate dose constraints are dependent on PTV
size, mean D2cm and R50% for each planning technique
would not best represent the cohort. Therefore, the
absolute difference (if any), from the no deviation
constraint was calculated. For example, if the no
deviation constraint for D2cm was 30 Gy, and the
technique achieved 32 Gy, then this would result in a
value of 2. Conversely, if another technique achieved
29.5 Gy at D2cm, this would give a value of 0.5.
Therefore, a D2cm or R50% value of 0 represents
compliance with a no deviation.
Table 2. Acceptable dose spillage guidelines from RTOG 1021.
Ratio of prescription
isodose volume to the
PTV
Ratio of 27 Gy isodose
volume to the PTV R50%
Maximum dose at 2 cm
from PTV in any
direction as % of
prescribed dose (PD).
D2cm (gy) = % 9 PD
Percent of lung
receiving 20 Gy total of
more V20 (%) PTV volume (cc)
Deviation Deviation Deviation Deviation
None Acceptable None Acceptable None Acceptable None Acceptable
<1.2 <1.5 <5.9 <7.5 <50.0 <57.0 <10 <15 1.8
<1.2 <1.5 <5.5 <6.5 <50.0 <57.0 <10 <15 3.8
<1.2 <1.5 <5.1 <6.0 <50.0 <58.0 <10 <15 7.4
<1.2 <1.5 <4.7 <5.8 <50.0 <58.0 <10 <15 13.2
<1.2 <1.5 <4.5 <5.5 <54.0 <63.0 <10 <15 22.0
<1.2 <1.5 <4.3 <5.3 <58.0 <68.0 <10 <15 34.0
<1.2 <1.5 <4.0 <5.0 <62.0 <77.0 <10 <15 50.0
<1.2 <1.5 <3.5 <4.8 <66.0 <86.0 <10 <15 70.0
<1.2 <1.5 <3.3 <4.4 <70.0 <89.0 <10 <15 95.0
<1.2 <1.5 <3.1 <4.0 <73.0 <91.0 <10 <15 126.0
<1.2 <1.5 <2.9 <3.7 <77.0 <94.0 <10 <15 163.0
Deviation values can be interpolated as required.
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Statistical methodology
Statistical analyses was performed using R statistical
software (http://www.r-project.org). To compare coplanar
and non-coplanar arrangements statistical tests for paired
data were performed with the normality of the data tested
using the Shapiro–Wilk test. The paired Student
parametric test has been used for normally distributed
data and Wilcoxon signed-rank non parametric test for
non-normally distributed data. Statistical significance was
defined as P ≤ 0.05.
Results
Median patient age was 76, with 70% being male. Median
PTV size was 27.5 cm3 (22.8–79.1 cm3). In 50% of cases,
the PTV was overlapping the CW. There were between 6
and 8 non-coplanar beams for the 10NC technique. The
10NC beam arrangement was the only technique where
the number of non-coplanar beams was varied and the
resultant plans met the dosimetric criteria. Across all
techniques, only 19 of the 60 plans had no more than 2
minor protocol deviations. Total mean monitor units
(MU) for the 7C, 9C, 7NC, 9NC, 10NC and 13C were
2867.65, 3019.54, 2919.23, 2996.87, 3225.36 and 3088.51
respectively. The largest difference in MUs was between
the 7C and 10NC with a total of 357.71 MU. Plans were
delivered at 600 MU/min.
Protocol deviations
A summary of the plan deviations, relative to RTOG 1021
(Table 2) is presented in Table 3. Overall, as the number
of beams increased, there were fewer protocol deviations.
Only on one occasion was the 10NC beam arrangement
unable to produce an acceptable plan. In this case the
PTV was overlapping the CW by 6.7 cm3 and the
maximum dose could not be lowered to 56.7 Gy (105%),
while maintaining PTV coverage.
PTV coverage
Table 5 reports the PTV coverage for all beam
arrangements. No statistically significant difference was
found between PTV coverage for coplanar versus non-
coplanar techniques (P = 0.47 and P = 0.87 for PTV54Gy
and PTV48.6Gy respectively). The median prescription
isodose, independent of technique was 68% (60.9–87%).
Median prescription isodoses values and ranges were
68.4% (63.8–85.7%), 67.9% (62.2–86.9%), 66.8% (63.2–
85.8%), 68.2% (63.3–86.4%), 62.6% (60.9–87%) and
68.8% (63.3–87%) for the 7C, 9C, 7NC, 9NC, 10NC and
13C plans respectively. Across all techniques, median
prescription isodoses were 65.8% for PTVs not
overlapping the CW, and 74.6% for PTVs overlapping the
CW.
High and intermediate constraints
The recorded D2cm and R50% deviations are reported in
Table 4. The D2cm values for combined techniques were
1.14 and 0.66 for all coplanar and all non-coplanar
arrangements respectively with a non-significant P value
of 0.19. Combined techniques recorded a R50% value of
1.06 for coplanar, and 0.62 for non-coplanar with a
significant P value of <0.0001. CI values, different to
D2cm and R50% constraints are independent of PTV size
and can be reported as the actual value. The mean CI
values are reported in Table 5 with no statistically
significant difference (P = 0.71).
Organs at risk
Forty-three percent (n = 26) of plans had OAR tolerance
dose violations, independent of technique. The
maximum rib dose was responsible for the majority of
protocol deviations. Five patients had PTVs overlapping
the CW, limiting the rib to a maximum dose of
Table 3. Beam arrangements and protocol deviations following
RTOG 1021 criteria.
7C 9C 13C 7NC 9NC 10NC
D2cm
None 1 2 6 2 4 10
Acceptable 6 8 4 6 6 0
Unacceptable 3 0 0 2 0 0
R50%
None 0 1 1 1 1 5
Acceptable 5 6 6 6 7 5
Unacceptable 5 3 3 3 2 0
CI
None 9 10 10 10 9 9
Acceptable 1 0 0 0 1 1
Unacceptable 0 0 0 0 0 0
OAR
None 4 4 3 4 4 5
Acceptable 1 1 1 1 1 4
Unacceptable 5 5 5 5 5 1
Total deviations
None 14 17 20 17 18 29
Acceptable 13 15 12 13 15 10
Unacceptable 13 8 8 10 7 1
Clinically suitable plans 1 2 2 3 3 9
D2cm, dose at any point 2 cm from the PTV; R50%, ratio of the
volume of half the PD to the volume of the PTV; CI, conformity index;
OAR, organ(s) at risk.
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56.7 Gy. For the 7C, 9C, 7NC, 9NC and 13C, the mean
maximum rib dose was on average for these plans,
60.5 Gy, 60.4 Gy, 60.5 Gy, 59.7 Gy and 60.4 Gy
respectively, all of which are over the allowed tolerance.
When removing patient 8 from the mean, the values for
the aforementioned techniques are 61.0 Gy, 60.7 Gy,
60.8 Gy, 60.0 Gy and 60.8 Gy respectively. The 10NC
technique had a mean maximum rib dose of 56.7 Gy
(excluding patient 8), the allowable tolerance of 105% of
the PD. There was however an increase in the lung
volume receiving 10.5 Gy and 11.4 Gy for the 10NC
compared to other techniques. The results in Table 5
show there was no statistically significant difference in
mean lung dose between the coplanar and non-coplanar
techniques (P = 0.68).
Discussion
This study investigated dosimetric factors of various
coplanar and non-coplanar beam arrangements for the
treatment of patients eligible for lung SABR with
heterogeneity corrections applied.
There were no significant differences in PTV coverage
(PTV54Gy or PTV48.6Gy) between beam arrangements,
given that they are compulsory protocol requirements
and coverage beyond 95% was only improved if the D2cm
and R50% constraints maintained a no deviation. The
10NC technique had the greatest PTV54Gy coverage of
95.37%, which is on average 0.5% higher than any other
technique.
The prescription isodoses for the plans were kept to
between 59% and 90% as recommended by RTOG20 and
Ding et al.20 The median prescription isodose value in
this study was 68% (62.6–68.7%), which is consistent
with previous reports on optimal prescription isodoses
for peripheral lung SABR.20 There was a difference in
prescription isodoses for plans where the PTV was
overlapping the CW. For those plans where PTV was
overlapping the CW the prescription isodose could be
increased from a median value of 65.8–74.6%. This is due
to the more dense soft tissue adjacent to one side of the
PTV and the reduced secondary electron range in the
tissue.
Furthermore, without comprehensive rib maximum
and dose volume constraints, it is considered best
practice to minimise the dose where possible.23–27
Because plans are prescribed in a way so the maximum
dose typically falls within the centre of the PTV, those
patients whose PTV overlaps a rib could have a
maximum dose that is well beyond the 105% of the PD.
Only the 10NC technique was able to consistently achieve
the maximum rib dose constraint while still achieving
95% coverage of the PTV (with the exception of patient
8). This is likely due to a greater ability to improve
shielding of the rib by increasing the number of non-
coplanar beams coupled with a higher prescription
isodose attainable on the CW.
The dosimetric study by Lim et al.15 performed
without a tissue heterogeneity correction found that
increasing the number of non-coplanar beams increased
the possibility of achieving intermediate dose constraints.
Our study accounted for tissue heterogeneity and
confirmed that an increase in non-coplanar beams
resulted in less protocol deviations. The greatest protocol
deviations were found for the 7 and 9 field all coplanar
beam arrangements. There were 13 and 8 instances
respectively, where these techniques had major protocol
deviations (Table 3). The 10NC was found to produce
PTV54Gy (%)
PTV48.6Gy
(%)
Mean lung
dose (Gy)
R50%
(Deviation)
D2 cm
(Deviation) CI
Coplanar
7 Fields 95.2 99.48 3.91 1.22 3.12 0.79
9 Fields 95.12 99.59 4.12 1.05 1.16 0.80
13 Fields 95.09 99.63 4.26 0.91 0.86 0.82
Non-coplanar
7 Fields 95.07 99.58 4.10 0.79 2.06 0.80
9 Fields 95.12 99.57 4.13 0.71 0.70 0.81
10 Fields 95.6 99.58 4.38 0.35 0.76 0.81
Mean values
All coplanar 95.14 99.57 4.01 1.10 1.14 0.80
All non-coplanar 95.26 99.58 4.12 0.62 0.66 0.80
P-value 0.47 0.87 0.09 <0.0001 0.19 0.71
PTV54Gy, percentage of the PTV receiving 54 Gy; PTV48.6Gy, percentage of the PTV receiving
48.6 Gy; D2cm, dose at any point 2 cm from the PTV; R50%, ratio of the volume of half the
prescription dose to the volume of the PTV; CI, conformity index.
Table 4. Mean dose statistics for each
technique, categorised into coplanar and
non-coplanar and mean values for all
coplanar and non-coplanar techniques
combined with associated P-values.
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the best plan with only one protocol deviation for the
maximum rib dose on patient 8 (59.1 Gy).
The dosimetric advantages of using non-coplanar
beams has previously been reported, however, the results
of this study illustrate that non-coplanar beams are
necessary to meet the intermediate and OAR dosimetric
constraints for any single plan.28 We demonstrated that
there is a statistically significant difference in the volume
of the 27 Gy isodose (R50%), for coplanar versus non-
coplanar techniques. Furthermore, there was no case
where any technique aside from the 10NC was able to
produce a plan with no protocol deviations. Increasing
the number of fields (13C) resulted in a slight
improvement when compared to either of the coplanar
and non-coplanar 7 and 9 field techniques with fewer
protocol deviations in regards to the intermediate dose.
However, it was not able to replicate the intermediate
dose sparing achievable with the 10NC technique.
Figure 1 demonstrates a dose wash of all 6 techniques
through the isocentre highlighting the reduction in
intermediate dose achievable with the 10NC technique.
In theory, increasing the number of beams reduces the
dose delivered through each beam, spreading out the low
dose and overlapping beams, resulting in a lower
intermediate dose. This is the philosophy of SABR and
allows for a steep isotropic fall off and is shown clearly
in our study.
Our findings differ from those reported by Richmond
et al. where in 89.5% of cases a 7 field, all coplanar
technique had 2 or less minor deviations.16 They too
accounted for heterogeneity correction, but used the less
stringent intermediate dose constraints from the ROSEL
trial.18 The difference in intermediate dose constraints
between RTOG 1021 and ROSEL significantly alters
which beam arrangements are deemed acceptable. All the
techniques tested in this study had intermediate doses
that were acceptable following the ROSEL guidelines.
However, following RTOG 1021 criteria we report that a
7 field technique, with beams entering through only the
ipsilateral lung produced no plans with equal to, or less
than 2 minor deviations. The difference in acceptable
D2cm and R50% constraints is believed to be the main
reason for disparity.
The EORTC recommend avoiding the use of non-
coplanar beams as this increases the treatment time, and
chance of intra-fraction motion.8 Furthermore, Purdie
et al.29 suggest that for treatment times >34 minutes
intra-fraction motion can increase by up to 5 mm. The
trade off between small gains in intermediate dose
sparing versus increased treatment time and the
potential for intra-fractional error with increasing non-
coplanar beams should be critiqued on an individual
patient basis.Ta
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Conclusion
Increased use of non-coplanar beams for 3-dimensional
conformal radiation therapy lung SABR allows for
improved control of intermediate dose objectives and
produces fewer protocol deviations when correcting for
tissue heterogeneity and following RTOG 1021
guidelines. A technique using 10 beams, six or more of
which were non-coplanar provided the greatest
compliance to high- and intermediate dose constrains,
while lowering doses to some critical structures.
However, increased non-coplanar beams results in an
increased treatment time that needs to evaluated for
each individual patient. The ability to deliver adequate
PTV coverage and acceptable intermediate doses using
coplanar techniques may be possible with novel
techniques such as intensity modulated radiation therapy
or volumetric modulated arc therapy and will be the
subject of future work.
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